Abstract

Alzheimer’s disease (AD) is the most pervasive form of neurodegenerative dementia affecting the global population today. Efforts to develop pharmacological intervention to halt or reverse the progression of AD have proven unsuccessful, resulting in insufficient treatment options for patients with AD which possess limited therapeutic benefits such as symptom management and slowing the inevitable progression of the disease. The lack of effective medications to treat AD has led to an urgent effort to fill this therapeutic gap, prompting researchers to further investigate the proposed anti-inflammatory and neuroprotective properties of cannabinoids in neurological diseases. This paper will review the current literature related to cannabinoids as potential therapeutic agents in the context of neurodegenerative disease.